ONKT-101

N/A

Report date: 2024/07/01 16:17:40

Base Information

Drug NameONKT-101

Drug Alias NameONKT-101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIreland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesONK Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesONK Therapeutics Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A